Kymera Results Presentation Deck

Pathway Program IL-1R/TLR JAK/STAT p53 Collaboration Discovery Pipeline IRAK4 IRAKIMID (IRAK4, Ikaros, Aiolos) STAT3 STAT3 MDM2 Confidential Kymera's Pipeline of Novel Protein Degraders Indication(s) Immuno-inflammatory Diseases: HS, AD, RA, others MYD88MT Tumors Liquid & Solid Tumors Autoimmune & Fibrotic Diseases Liquid & Solid Tumors Confidential Several Discovery Programs Discovery IND Enabling 6 Undisclosed Programs KT-474 Multiple molecules staged as potential back ups if needed 0 KT-413 KT-333 KT-253 Phase 1 Collaboration *Option to participate equally in the development and commercialization of Sanofi-partnered programs in the US. RA: Rheumatoid arthritis, AD: Atopic Dermatitis, HS: Hidradenitis suppurativa KYMERA ©2022 KYMERA THERAPEUTICS, INC. Multiple programs in immune-inflammatory and oncology indications anticipated to deliver ≥ 1 IND/year 6 targets in 5 disease areas outside of immunology-inflammation and oncology Phase 2 = Oncology Next Milestones Phase 2 Start 2023 Clinical Activity 2023 Clinical Activity 2023 Phase 1 Start 2023 ≥ 1 DC Annually = Immunology-Inflammation Rights* KYMERA sanofi KYMERA KYMERA KYMERA KYMERA KYMERA sanofi KYMERA VERTEX PAGE 5

View entire presentation